Evidence map›Paper›PMID 39220871›Full record

ReviewActa pharmaceutica Sinica. B2024

Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy.

Xueqiang Peng, Jianjun Fang, Chuyuan Lou, Liang Yang, Shaobo Shan, Zixian Wang, Yutong Chen, Hangyu Li, Xuexin Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xueqiang PengDepartment of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China.
Jianjun FangDepartment of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China.
Chuyuan LouDepartment of Ophthalmology, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an 710004, China.
Liang YangDepartment of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China.
Shaobo ShanDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 10050, China.
Zixian WangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China.
Yutong ChenDepartment of Pathology, Medical College, Jinan University, Guangzhou 510632, China.
Hangyu LiDepartment of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China.
Xuexin LiDepartment of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of cancer immunotherapy has imparted a transformative impact on cancer treatment paradigms by harnessing the power of the immune system. However, the challenge of practical and precise targeting of malignant cells persists. To address this, engineered nanoparticles (NPs) have emerged as a promising solution for enhancing targeted drug delivery in immunotherapeutic interventions, owing to their small size, low immunogenicity, and ease of surface modification. This comprehensive review delves into contemporary research at the nexus of NP engineering and immunotherapy, encompassing an extensive spectrum of NP morphologies and strategies tailored toward optimizing tumor targeting and augmenting therapeutic effectiveness. Moreover, it underscores the mechanisms that NPs leverage to bypass the numerous obstacles encountered in immunotherapeutic regimens and probes into the combined potential of NPs when co-administered with both established and novel immunotherapeutic modalities. Finally, the review evaluates the existing limitations of NPs as drug delivery platforms in immunotherapy, which could shape the path for future advancements in this promising field.

Indexed as

Blood–brain barrierCancerCancer immunotherapyDrug deliveryEngineered nanoparticlesNanomaterialNanomedicineTumor-barrier

Identifiers

PMID39220871
PMCPMC11365410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.